Can Buprenorphine Cause Erythema Multiforme Major?
There is no documented evidence that buprenorphine causes erythema multiforme major. The FDA drug label for buprenorphine does not list erythema multiforme as an adverse reaction, and available research only reports contact dermatitis from transdermal formulations 1.
Evidence Review
FDA Drug Label Data
The official FDA labeling for buprenorphine sublingual tablets extensively details adverse reactions but does not mention erythema multiforme, Stevens-Johnson syndrome (SJS), or toxic epidermal necrolysis (TEN) 1. The documented adverse events focus on:
- Neonatal opioid withdrawal syndrome
- Pregnancy-related risks
- Respiratory depression
- Hepatotoxicity
Post-Marketing Surveillance
Analysis of FDA Adverse Event Reporting System (FAERS) data from long-acting injectable buprenorphine formulations during the first 18 months post-launch identified the most common adverse events as withdrawal syndrome, injection site reactions (pain, erythema, discharge), drug dependence, nausea, and fatigue 2. Erythema multiforme was not reported among the 3,848 adverse event terms for monthly injectable buprenorphine or 2,080 terms for weekly/monthly formulations.
Published Case Reports
The only documented hypersensitivity reaction to buprenorphine in the literature is allergic contact dermatitis from transdermal buprenorphine patches 3. This manifested as:
- Persistent, pruritic erythematous plaques at patch application sites
- Generalized skin eruption in two of five cases
- Positive patch testing to the active drug (not the placebo patch)
- Delayed hypersensitivity (Type IV) mechanism
This is fundamentally different from erythema multiforme major, which is typically triggered by infections (especially Mycoplasma pneumoniae) or certain medications through different immunologic mechanisms 4.
Clinical Context
Drugs That Actually Cause Erythema Multiforme
The 2022 Drug Allergy Practice Parameter identifies NSAIDs—particularly oxicam derivatives (meloxicam, piroxicam), acetic acid derivatives (diclofenac), and selective COX-2 inhibitors—as common causes of severe cutaneous adverse reactions including erythema multiforme 5. Buprenorphine is not mentioned in this comprehensive guideline covering drug-induced cutaneous reactions.
Important Caveat: Protopathic Effect
NSAIDs (particularly ibuprofen) and acetaminophen are often started when patients develop prodromal symptoms of SJS/TEN or erythema multiforme (fever, mucosal involvement), leading to false attribution of causality 5. Similarly, if a patient on buprenorphine develops erythema multiforme from another cause (infection, other medication), buprenorphine might be incorrectly implicated.
Clinical Recommendation
If a patient on buprenorphine develops erythema multiforme major:
Search for alternative causes first:
- Recent Mycoplasma pneumoniae, HSV, or other infections 4
- Concurrent medications, especially NSAIDs, antibiotics, anticonvulsants
- Other new exposures
Do not discontinue buprenorphine reflexively unless all other causes are excluded, given:
- No documented association in FDA labeling or post-marketing surveillance
- Risk of precipitating opioid withdrawal and relapse
- Potential harm from untreated opioid use disorder
If buprenorphine must be discontinued (after excluding other causes):
- Transition to alternative opioid agonist therapy (methadone)
- Avoid transdermal buprenorphine if contact dermatitis is suspected
Manage the erythema multiforme major according to standard protocols:
- Systemic corticosteroids as first-line
- Consider IVIg for severe or steroid-refractory cases 4
The absence of any documented cases linking buprenorphine to erythema multiforme major in extensive FDA surveillance data, drug labeling, and medical literature strongly suggests this is not a recognized adverse effect of the medication.